Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AMG 256 |
Synonyms | |
Therapy Description |
AMG 256 is a fusion protein comprising of mutated IL-21 fused to an antibody targeting PD-1, which binds to and inhibits PD-1 signaling, potentially leading to the restoration of the T-cell mediated immune response (NCI Thesaurus, Journal for ImmunoTherapy of Cancer 2020;8) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 256 | AMG-256|AMG256|Latikafusp | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | AMG 256 is a fusion protein comprising of mutated IL-21 fused to an antibody targeting PD-1, which binds to and inhibits PD-1 signaling, potentially leading to the restoration of the T-cell mediated immune response (NCI Thesaurus, Journal for ImmunoTherapy of Cancer 2020;8) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04362748 | Phase I | AMG 256 | Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | Completed | USA | ESP | BEL | AUS | 0 |